tbuckley/cabot-search huggingface dataset:
POS0921 EFFICACY AND SAFETY OF ACEMETACIN IN THE TREATMENT OF 1215 ACTIVE ANKYLOSING SPONDYLITIS PATIENTS: DATA FROM A PROSPECTIVE COHORT MANAGED BY SMART-PHONE SPONDYLOARTHRITIS MANAGEMENT SYSTEM
Authors: J. Zhang, L. Hu, X. Ji, Y. Wang, F. Huang
Journal: Annals of the Rheumatic Diseases (2021)

Background: Biological DMARDs have widely used in the treatment of AS in last two decades, but NSAIDs still serves as a cornerstone in the treatment. Given the wide use of Acemetacin in AS and relative lack of clinical evidence on the selection of NSAIDs in the treatment of AS, the investigation on acemetacin treating AS is of great significance. Objectives: Our study aims to investigate efficacy and safety of acemetacin in the treatment of AS. Methods: Data on efficacy and safety is available in 1215 patients from the Chinese Ankylosing Spondylitis Imaging Cohort (CASPIC), which is collected through the Smart-phone SpondyloArthritis Management System (SpAMS) [1] . Patients’ self-assessments are completed online at baseline and every subsequent clinic visit. Physician-reported assessments, laboratory tests, and treatments were recorded by rheumatologists at every clinic visit. Results: 1215 patients with AS were registered, of whom 992 were treated with acemetacin and 123 were treated with other NSAIDs. The results showed that total back pain and BASFI were significantly improved after three-month treatment of acemetacin, while comparing to other NSAIDs ( P =0.027 and 0.015, respectively). After six-month treatment, patients taking acemetacin showed greater improvement in PGA ( P =0.013), total back pain ( P =0.049), night back pain ( P =0.047), BASFI ( P =0.042), ASDAS ( P =0.007) and CRP ( P =0.032) compared to those taking other NSAIDs. During the follow-up periods, no serious adverse events were reported. Mild abnormal liver function occurred in nine patients (9/992) treated with acemetacin and in six patients treated with other NSAIDs (6/123). See Table 1 for details. Conclusion: Acemetacin showed better efficacy and acceptable safety profile in the treatment of active ankylosing spondylitis comparing with other NSAIDs. References: [1]Ji, X., et al., Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study. BioMed research international, 2019. 2019: p. 2171475. Table 1. The comparation of two groups at 0, 3 and 6 months after treatment Baseline 3 months 6 months 95%CI P 95%CI P 95%CI P PGA -0.13(-0.49, 0.24) 0.494 -0.28(-0.74, 0.18) 0.235 -0.59(-1.06, -1.13) 0.013* Total back pain -0.03(-0.37, 0.32) 0.889 -0.50(-0.94, -0.06) 0.027* -0.44(-0.88, -0.002) 0.049* Night back pain 0.01(-0.36, 0.38) 0.956 -0.30(-0.75, 0.16) 0.203 -0.46(-0.91, -0.006) 0.047* BASFI -0.30(-0.59, 0.004) 0.053 -0.55(-0.99, -0.11) 0.015* -0.34(-0.67, -0.01) 0.042* ASDAS -0.10(-0.29, 0.08) 0.287 -0.15(-0.46, 0.16) 0.342 -0.41(-0.70, -0.11) 0.007* CRP -4.39(-8.87, 0.10) 0.055 0.91(-10.39, 12.21) 0.874 -7.86(-15.03, -0.68) 0.032* Disclosure of Interests: None declared
Equity and the JAMA Network
Authors: Phil B. Fontanarosa, Annette Flanagin, John Z. Ayanian, Robert O. Bonow, Neil M. Bressler, Dimitri Christakis, Mary L. Disis, S. Andrew Josephson, Melina R. Kibbe, Dost Öngür, Jay F. Piccirillo, Rita F. Redberg, Frederick P. Rivara, Kanade Shinkai, Clyde W. Yancy
Journal: JAMA (2021)

The key objective of JAMA is "To promote the science and art of medicine and the betterment of the public health"; similar objectives and mission statements are supported by all 12 JAMA Network Journals.Together this family of journals is committed to publishing the best research, reviews, and opinion articles to advance medical science, promote public health, and improve patient care.The ultimate goal is to promulgate truth in science and medicine.On
scDesign2: a transparent simulator that generates high-fidelity single-cell gene expression count data with gene correlations captured
Authors: Tianyi Sun, Dongyuan Song, Wei Vivian Li, Jingyi Jessica Li
Journal: Genome biology (2021)

A pressing challenge in single-cell transcriptomics is to benchmark experimental protocols and computational methods. A solution is to use computational simulators, but existing simulators cannot simultaneously achieve three goals: preserving genes, capturing gene correlations, and generating any number of cells with varying sequencing depths. To fill this gap, we propose scDesign2, a transparent simulator that achieves all three goals and generates high-fidelity synthetic data for multiple single-cell gene expression count-based technologies. In particular, scDesign2 is advantageous in its transparent use of probabilistic models and its ability to capture gene correlations via copulas.
Diagnosis of Ectopic Pancreas in Small Intestine With 18F-DOPA PET/CT
Authors: Nicolas Jacquet-Francillon, Guillaume Passot, Alexandre Galan, Jérémie Tordo, Anthony Dhomps
Journal: Clinical Nuclear Medicine (2021)

Abstract A 77-year-old man was referred for a PET/CT 18 F-FDG after incidental discovery of a lobulated jejunal lesion during surgery for an abdominal aortic aneurysm. The lesion was not removed due to the risk of digestive perforation. PET/CT 18 F-FDG did not show pathologic hypermetabolism. Subsequently, we decided to perform PET/CT 18 F-DOPA to better characterize this incidentaloma. A moderate uptake was showed, less than the pancreas. After multidisciplinary discussion, taking into account macroscopic and imaging aspects, the hypothesis of an ectopic pancreas was retained, allowing the exclusion of surgical excision.
OP0057 A PERSONALISED RITUXIMAB RETREATMENT APPROACH BASED ON CLINICAL AND B-CELL BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS
Authors: J. Arnold, E. Vital, S. Dass, A. Aslam, A. Rawstron, S. Savic, P. Emery, M. Y. MD Yusof
Journal: Annals of the Rheumatic Diseases (2021)

Background: Time-to-relapse after rituximab for ANCA-associated vasculitis (AAV) is variable and optimal retreatment strategy has been unclear. We previously showed that repopulation of naïve B-cells at 6 months predicts sustained response [1]. Objectives: In AAV following rituximab induction, to evaluate clinical and B-cell predictors of relapse in order to develop a retreatment algorithm. Methods: An observational study was conducted in 60 rituximab-treated AAV patients followed for over 10 years. Complete response (CR) was defined as Birmingham Vasculitis Activity Score v3.0 = 0. Retreatment was given on clinical relapse, defined as new features or worsening of persistent disease (not by biomarker status). Peripheral B-cell subsets were measured using highly sensitive flow cytometry. Predictors were tested using multivariable Cox-Regression. Results: Median times-to-retreatment for rituximab cycles 1-5 were 87, 71, 65, 59 and 86 weeks. Over 417 patient-years follow-up, 137 relapses occurred in 50 patients; 16 (in 14 patients) were major (renal=7, neurological=4, ENT=3 and respiratory=2). The major-relapse rate was 3.8/100 patient-years. In multivariable analysis, concomitant immunosuppressant [HR 0.48 (95% CI 0.24–0.94)], achieving CR [0.24 (0.12–0.50)] and naïve B-cell repopulation at 6 months [0.43 (0.22–0.84)] were associated with longer time-to-relapse. Higher baseline memory B-cells [1.01 (1.00–1.02)] were associated with a shorter time-to-relapse. AUROC for prediction of time-to-relapse was greater if guided by naïve B-cell repopulation than if ANCA and/or CD19+ return at 6 months had been used, 0.82 and 0.52 respectively. Conclusion: These data suggest that all patients should receive concomitant oral immunosuppressant. Those with incomplete response or with absent naïve B-cells should be retreated at 6 months. Patients with complete response and naïve repopulation at 6 months should not receive fixed retreatment. This algorithm could reduce hypogammaglobulinaemia due to unnecessary retreatment. Figure 1. A personalised retreatment algorithm for rituximab in ANCA-associated vasculitis References: [1]Md Yusof et al. Annals of rheumatic diseases (2015) PMID: 25854586. Disclosure of Interests: Jack Arnold: None declared, Edward Vital Speakers bureau: Roche, GSK and AstraZeneca, Consultant of: Roche, GSK and AstraZeneca, Grant/research support from: Roche, GSK and AstraZeneca, Shouvik Dass Speakers bureau: Roche and GSK, Aamir Aslam: None declared, Andrew Rawstron: None declared, Sinisa Savic: None declared, Paul Emery Speakers bureau: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Consultant of: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Md Yuzaiful Md Yusof: None declared
Ghrelin promotes astrocytoma cell invasion via functional growth hormone secretagogue receptors (GHS-R), and regulates leptin induced MCP-1 expression
Authors: Vishwa Deep-Dixit, Ashani T. Weeraratna, Audrey N. Kalehua, Eric M. Schaffer, Dennis D. Taub
Journal: Cancer Research (2004)

1956  Ghrelin, a recently discovered stomach derived hormone, is an endogenous ligand for growth hormone secretagogue receptor (GHS-R) and is a potent stimulator of pituitary GH release, food intake and plays a critical role in adipogenesis. Obesity has now been identified as a major risk factor in development of many cancers, but the role of obesity–related hormones such as ghrelin in tumors of CNS origin is currently unknown. Our initial studies focused on the presence and functionality of GHS-R on CCF-STTG1, U-87, U-118 and SW1008 human astrocytoma cells. Real time PCR analysis revealed the presence of GHS-R1a, as well as leptin receptor (Ob-R) mRNA and protein in all of our astrocytoma cell lines. Upon treatment of these tumor cells with ghrelin, the GHS-R was found to colocalize with Rac, within the membrane ruffles on the leading edge of cells, and also consistently increased cell motility. In addition, ligations of GHS-R with ghrelin led to the release of Ca2+ from its intracellular stores. To specifically investigate and assign a functional role for ghrelin receptors in astrocytoma cells, we designed an siRNA against the coding region of GHS-R 1a. Knockdown of ghrelin receptors by siRNA led to a significant inhibition of invasion in cells lacking GHS-R, as compared to a scrambled control siRNA sequence. Further, ghrelin-induced invasion was significantly inhibited by siRNA against GHS-R1a, suggesting that ghrelin might function through the GHS-R 1a receptors in human astrocytoma cells. Given the apparent mutually antagonistic effects of ghrelin and the anorexigenic hormone, leptin, in hypothalamus, the potential regulatory role of these hormones in controlling cytokine and chemokine expression was also examined. Ghrelin exerted no effect on basal or IL-1 stimulated, IL-6, IL-8 and MCP-1 secretion from CCFSTTG1 cell. Interestingly, leptin increased MCP-1 mRNA and protein in these cells, and ghrelin significantly inhibited leptin-induced MCP-1 expression and secretion without affecting IL-6 and IL-8 expression. In addition, leptin was found to regulate ghrelin’s actions by attenuating the expression of GHS-R, while ghrelin in turn inhibited Ob-R expression in astrocytoma cells. Interestingly,. Further, GHS-R 1a and Ob-R were found to be expressed in different grades of human astrocytoma tumors derived from right and left frontal as well as occipital lobes of brain. Our findings demonstrate a novel role for the hormone peptides ghrelin and leptin in astrocytoma cell function. This autoregulatory hormonal feedback loop may play a role in tumor progression within astrocytoma cells.
Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier
Authors: Lael M. Yonker, Tal Gilboa, Alana F. Ogata, Yasmeen Senussi, Roey Lazarovits, Brittany P. Boribong, Yannic C. Bartsch, Maggie Loiselle, Magali Noval Rivas, Rebecca A. Porritt, Rosiane Lima, Jameson P. Davis, Eva J. Farkas, Madeleine D. Burns, Nicola Young, Vinay S. Mahajan, Soroush Hajizadeh, Xcanda I. Herrera Lopez, Johannes Kreuzer, Robert Morris, Enid E. Martinez, Isaac Han, Kettner Griswold, Nicholas C. Barry, David B. Thompson, George Church, Andrea G. Edlow, Wilhelm Haas, Shiv Pillai, Moshe Arditi, Galit Alter, David R. Walt, Alessio Fasano
Journal: Journal of Clinical Investigation (2021)

BACKGROUND. Weeks after SARS-CoV-2 infection or exposure, some children develop a severe, life-threatening illness called multisystem inflammatory syndrome in children (MIS-C). Gastrointestinal (GI) symptoms are common in patients with MIS-C, and a severe hyperinflammatory response ensues with potential for cardiac complications. The cause of MIS-C has not been identified to date.
POS0036 AN ARTIFICIAL INTELLIGENCE MODEL IN RHEUMATOLOGY: INTERPRETATION OF THE SACROILIAC JOINT GRAPHY IN ANKYLOSING SPONDYLITIS
Authors: A. C. Genç, Z. N. Kaya, F. Turkoglu Genc, L. Genc Kaya, Z. Öztürk, D. Karatas, S. M. Turk, E. Gönüllü
Journal: Annals of the Rheumatic Diseases (2021)

Background: There is an average of 8 years delay in the diagnosis of ankylosing spondylitis (AS). The most important danger of late diagnosis is that the disease can cause physical and functional disability (2). There is no specific diagnostic biomarker for AS. Sacroiliac joint (SIJ) radiography is frequently used in the diagnosis and follow-up of AS due to its easy accessibility and low cost. It can be classified as grade 0, 1, 2, 3, 4, and these classes may not be sharply separated from each other (3). Objectives: Interpretation of the SIJ radiography may differ from physician to physician. In fact, the same physician may interpret it differently at different times (3). We wanted to find a solution to the intraobserver disagreement problem with the artificial intelligence model. Methods: The SIJ radiography of 590 patients who applied to our center were divided into 3 categories as right and left, separately, grade 0, grade 1-2, grade 3-4, and an educational data set was prepared for the object recognition method. 488 images were augmented through noise from 490 images in the training data. 242 articular objects were trained for grade 0, 278 for grade 1-2, and 1426 for grade 2-3. The model was tested with 100 images for 36 joint objects for grade 0, 29 for grade 1-2, and 135 for grade 3-4 to create a computer vision-artificial intelligence model (image 1). Results: Training performance is 70% for grade 0, %63 for grade 1-2, %90 for grade 3-4 and test performance is %52 for grade 0, %24 for grade 1-2, %86 intersection over union (I/U:Intersection over Union is a form of measurement used to indicate the accuracy of an object detector.) for grade 3-4. The mean average precision (mAP) score of our object detection model is %65.9 for test data set (image 1). The estimation quality of the model can be affected by the distribution and number of each class. Conclusion: The experience of the x-ray technician, dose adjustment, and position differences due to patient compliance complicate the standardization of SIJ radiography and this may cause interobserver disagreement (3). Artificial intelligence models to be created with a larger and homogeneous data set in order to ensure objective standardization in the interpretation of the SIJ graph can help physicians. References: [1]Braun J. ‘Axial spondyloarthritis including ankylosing spondylitis’ Rheumatology (Oxford). 2018 1;57(suppl_6):vi1-vi3 [2]Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535-543. [3]van den Berg, R. et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. Arthritis Rheumatol 66, 2403–2411 (2014). Disclosure of Interests: None declared.
AB0775 MANY RARE AND SERIOUS LOCALIZATIONS IN ONE CASE WITH HEREDITARY EXOSTOSES
Authors: R. Sarraj, M. Ghali, R. Ben Chehida, G. Mouna, I. Bejia, J. Mahbouba, S. Zrour, M. Touzi, N. Bergaoui
Journal: Annals of the Rheumatic Diseases (2021)

Background: Multiple hereditary exostoses (MHE) is an inherited disorder of bone growth. People who have MHE grow exostoses or boney bumps on their bones that vary in size, location and number. Some localizations are rare but potentially serious such as ribs, spine or pelvis due to proximity to important structures. Objectives: The aim of this case report was to illustrate the clinical and radiographic features of some rare localizations of MHE. Methods: We are reporting a rare case of a thirty one-year-old male with severe localizations of MHE. Results: A thirty one-year-old male affected by hereditary multiple exostoses., not followed up, came to our consultation complaining about chest pain. On examination, he walks with a limp because of the unequalness of his limbs.The osteoarticular examination revealed numerous palpable osseous masses at the distal and proximal end of the 2 arms, 2 forearms, 2 thighs and 2 legs and at the right iliac wing. Neurological examination revealed vivid deep tendon reflexes, bilateral positive Hoffmann’sign and Babinski reflex associated with right hemiparesis. The pulmonary exam was normal. Medullary MRI showed medullary compression with spinal cord atrophy and sign of myelopathy of c1 c2 segment. The ct –scan revealed multiple exostosis, the two largest lesions were located in the second rib measuring 45mm * 35mm axially and 52mm in height compromising blood vessels, and in the right iliac bone with a retroperitoneal growing mass measuring 126 * 94 mm axially and 100 mm in height leading to a serious entrapment of the axial skeleton and the abdominal organs. It also confirmed thickening of the cartilage cap of the right iliac bone suggestive of malignant chondrosarcomatous transformation. Conclusion: Exostoses are the most common benign bone tumors. Its complications are rare but can cause a functional disability or even a vital risk. References: [1]Eke GK, Omunakwe HE, Echem RC. Hereditary multiple exostoses in a 15-year-old boy: A case report and review of literature. Niger J Paediatr. 2016;43(4):295. Disclosure of Interests: None declared
Trends and Characteristics of Manufactured Cannabis Product and Cannabis Plant Product Exposures Reported to US Poison Control Centers, 2017-2019
Authors: Julia A. Dilley, Janessa M. Graves, Ashley Brooks-Russell, Jennifer M. Whitehill, Erica L. Liebelt
Journal: JAMA Network Open (2021)

This cross-sectional study examines reports of cannabis exposure at US poison control centers for trends in patient and product characteristics, stratified by manufactured cannabis products and plant materials.
COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
Authors: Meseret Birhane, Sara Bressler, Gregory Chang, Thomas Clark, Layne Dorough, Marc Fischer, Louise Francois Watkins, Jason M. Goldstein, Kiersten Kugeler, Gayle Langley, Kristin Lecy, Stacey Martin, Felicita Medalla, Kiren Mitruka, Leisha Nolen, Katrin Sadigh, Robin Spratling, Gail Thompson, Alma Trujillo
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people.
In-Hospital outcome after stenting in women compared to men. Results from the registry of the brazilian society of interventional cardiology: CENIC
Authors: Amanda Guerra de Moraes Rego Sousa, Luiz A. P. Mattos, Marco Antonio Costa, Cantideo M. Campos Netto, Ângela Tavares Paes, Jamil Saad, Andre Labrunie, Alexandre Abizaid, Roberto Botelho, Ronaldo Bueno, Eulógio Martinez, Pierre Labrunie, Carlos Gottchall, Constantino Constantini, J. Eduardo M. R. Sousa, José Antônio Marin-Neto
Journal: Journal of the American College of Cardiology (2001)
POS1142 INTERLEUKIN-37: ASSOCIATIONS OF PLASMA LEVELS AND GENETIC VARIANTS IN GOUT
Authors: A. Navrátilová, V. Voclonová, H. Hulejova, L. Andres Cerezo, J. Zavada, K. Pavelka, L. Šenolt, B. Stiburkova
Journal: Annals of the Rheumatic Diseases (2021)

Background: IL-37, recently characterized IL-1 family member, has anti-inflammatory effects by suppression of IL-1ß and other proinflammatory cytokines. In this study we investigated the effects of genetics variants in IL-37 link with IL-37 plasma levels in a cohorts of patients with hyperuricemia/gout. Objectives: The aim of this study was to determine the association of IL-37 gene polymorphism and plasma IL-37 levels in patients with hyperuricemia and gout. Methods: The cohorts consisted of 50 control subjects, 50 subjects of primary hyperuricemia, 50 subjects of primary gout, 28 subjects of tophaceous gout and 19 subjects of acute gout flare. The analyzed cohorts were selected from a previously reported set of 250 hyperuricemia/gout patients and 132 normouricemic subjects (1) according to the descending level of serum urate. All coding regions and intron-exon boundaries of IL-37, exon 1-5, were amplified and sequenced directly. Comparisons of presence/absence of identified variants was performed using P-values binomial test. Levels of plasma IL-37 were measured using Enzyme-Linked ImmunoSorbent Assay. All tests were performed in accordance with standards set by the institutional ethics committees, which approved the project in Prague (no.6181/2015). Results: We identified 12 IL-37 genetic variants: five intron (rs28947188, rs2466448, rs3811045, rs3811048, rs2708944), and seven non-synonymous allelic variants (rs3811046, rs3811047, rs2708943, rs2723183, rs2723187, rs2708947, rs27231927). Minor allele frequency (MAF) of those variants in European population from ExAC databases were used for comparison. Our data showed that the rs28947188, rs3811045, rs3811046, rs3811047, rs2723187, rs2708947, and rs27231927 variants were under-represented in the Czech hyperuricemia, gout, and tophaceous gout cohort compared with the control cohort and general European population (P = 0.0082 – 0.0395). The levels of plasma IL-37 were significantly higher in patients with tophaceous gout compared to control subjects (P 0.0329) whereas no changes were observed in subjects with primary hyperuricemia, primary gout or acute gout flare compared to control subjects. However, IL-37 was elevated in cohorts of patients with gout, tophaceous gout and acute gout flare compared to primary hyperuricemia subjects (P 0.0198, 0.0005, 0.0099; respectively). Conclusion: Although further analyzes are needed to elucidate the role of IL-37 in the gout, our results show that genetic variants in anti-inflammatory cytokine IL-37 are probably implicated in the pathogenesis of gout. References: [1]Toyoda Y, et al. Functional characterization of clinically-relevant rare variants in ABCG2 identified in a gout and hyperuricemia cohort. Cells . 2019 Apr 18;8(4). Acknowledgements: This study was supported by the grant from the Czech Republic Ministry of Health RVO 00023728. Disclosure of Interests: None declared.